DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™
DeepHealth, a RadNet (NASDAQ: RDNT) subsidiary, has received FDA 510(k) clearance for TechLive™, a remote scanning solution for MR, CT, PET/CT, and Ultrasound procedures. The vendor-agnostic platform enables centralized operation and supervision of multiple imaging systems simultaneously.
During a pilot deployment at 64 New York facilities, TechLive™ helped achieve a 42% reduction in MRI room closure hours in Q2 2025 compared to Q2 2024. The system has already been implemented across over 300 RadNet imaging systems, improving operational efficiency and increasing access to complex procedures.
DeepHealth, una filiale di RadNet (NASDAQ: RDNT), ha ottenuto la approvazione FDA 510(k) per TechLive™, una soluzione di scansione remota per procedure di risonanza magnetica (RM), tomografia computerizzata (TC), PET/TC e ultrasuoni. La piattaforma indipendente dal fornitore consente la gestione centralizzata e la supervisione simultanea di più sistemi di imaging.
Durante un progetto pilota in 64 strutture di New York, TechLive™ ha contribuito a una riduzione del 42% delle ore di chiusura delle sale RM nel secondo trimestre 2025 rispetto allo stesso periodo del 2024. Il sistema è già stato implementato in oltre 300 sistemi di imaging RadNet, migliorando l'efficienza operativa e aumentando l'accesso a procedure complesse.
DeepHealth, una subsidiaria de RadNet (NASDAQ: RDNT), ha recibido la aprobación FDA 510(k) para TechLive™, una solución de escaneo remoto para procedimientos de RM, TC, PET/TC y ultrasonido. La plataforma independiente del proveedor permite la operación centralizada y supervisión simultánea de múltiples sistemas de imagen.
Durante un despliegue piloto en 64 instalaciones de Nueva York, TechLive™ ayudó a lograr una reducción del 42% en las horas de cierre de salas de resonancia magnética en el segundo trimestre de 2025 en comparación con el mismo periodo de 2024. El sistema ya se ha implementado en más de 300 sistemas de imagen RadNet, mejorando la eficiencia operativa y aumentando el acceso a procedimientos complejos.
DeepHealth는 RadNet(NASDAQ: RDNT)의 자회사로서 MR, CT, PET/CT, 초음파 절차를 위한 원격 스캐닝 솔루션인 TechLive™에 대해 FDA 510(k) 승인을 받았습니다. 이 공급업체 독립형 플랫폼은 여러 영상 시스템을 동시에 중앙에서 운영 및 감독할 수 있게 합니다.
뉴욕의 64개 시설에서 파일럿 배포 기간 동안 TechLive™는 2025년 2분기에 2024년 2분기 대비 MRI실 폐쇄 시간을 42% 감소시키는 데 기여했습니다. 이 시스템은 이미 300개 이상의 RadNet 영상 시스템에 도입되어 운영 효율성을 높이고 복잡한 절차에 대한 접근성을 향상시켰습니다.
DeepHealth, une filiale de RadNet (NASDAQ : RDNT), a obtenu l'autorisation FDA 510(k) pour TechLive™, une solution de téléscanning pour les procédures d’IRM, de scanner, de PET/CT et d’échographie. Cette plateforme indépendante du fournisseur permet une gestion centralisée et la supervision simultanée de plusieurs systèmes d’imagerie.
Lors d’un déploiement pilote dans 64 établissements de New York, TechLive™ a permis une réduction de 42 % des heures de fermeture des salles d’IRM au deuxième trimestre 2025 par rapport au deuxième trimestre 2024. Le système a déjà été déployé sur plus de 300 systèmes d’imagerie RadNet, améliorant l’efficacité opérationnelle et facilitant l’accès aux procédures complexes.
DeepHealth, eine Tochtergesellschaft von RadNet (NASDAQ: RDNT), hat die FDA 510(k)-Zulassung für TechLive™ erhalten, eine Fern-Scanning-Lösung für MRT-, CT-, PET/CT- und Ultraschallverfahren. Die herstellerunabhängige Plattform ermöglicht die zentrale Steuerung und Überwachung mehrerer Bildgebungssysteme gleichzeitig.
Während eines Pilotprojekts in 64 Einrichtungen in New York trug TechLive™ im zweiten Quartal 2025 zu einer 42%igen Reduzierung der Schließzeiten von MRT-Räumen im Vergleich zum zweiten Quartal 2024 bei. Das System wurde bereits in über 300 RadNet-Bildgebungssystemen implementiert, verbessert die Betriebseffizienz und erhöht den Zugang zu komplexen Verfahren.
- FDA 510(k) clearance received for TechLive™ remote scanning solution
- 42% decrease in MRI room closure hours during Q2 2025 pilot deployment
- Successfully connected over 300 imaging systems across RadNet's network
- Addresses technologist shortage and enables simultaneous multi-location scanning
- Increases access to complex procedures and extends center operating hours
- Current technologist staffing shortages in radiology industry
- Inflationary wage pressure affecting operational costs
Insights
RadNet's TechLive remote scanning solution addresses critical technologist shortages, demonstrating significant operational improvements with potential revenue benefits.
The FDA 510(k) clearance for DeepHealth's TechLive™ represents a significant innovation in radiology operations. This remote scanning platform allows technologists to operate MR, CT, PET/CT, and Ultrasound equipment from centralized locations, addressing the growing gap between radiology workloads and qualified staff availability.
The technology has demonstrated measurable operational benefits in real-world deployment. In RadNet's New York facilities, TechLive™ contributed to a
What makes TechLive™ particularly valuable is its vendor-agnostic approach, allowing implementation across various equipment manufacturers. With over 300 imaging systems already connected, RadNet has demonstrated scale that suggests a proven implementation model.
The timing is strategic amid industry-wide challenges. The radiologist technologist shortage has created bottlenecks in imaging workflows nationwide, while inflation has driven up labor costs. By enabling technologists to operate multiple systems simultaneously, TechLive™ addresses both the workforce shortage and cost pressures.
The inclusion of ultrasound capability is particularly noteworthy, as this modality traditionally requires significant hands-on expertise. The remote guidance model could substantially improve access to specialized ultrasound procedures in underserved areas while maintaining quality standards.
- TechLive™ is a vendor-agnostic integrated solution enabling remote scanning of MR, CT, PET/CT, and Ultrasound procedures
- Amidst radiology technologist shortages, remote scanning in a command center configuration enables the workforce to scan at multiple locations simultaneously with a high level of expertise
- RadNet has connected more than 300 MR, CT, PET/CT, and Ultrasound systems with TechLive™, delivering operational efficiency and increased access to advanced procedures
LOS ANGELES and SOMERVILLE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and global leader in AI-powered health informatics, announced today that it has received FDA 510(k) clearance for TechLive™ - a remote scanning solution enabling centralized operation and supervision of MR, CT, PET/CT, and Ultrasound procedures. Amidst tech labor shortages and inflationary wage pressure, TechLive™ empowers technologists to scan for multiple locations, enables improved operational efficiency, extends center operating hours, and enhances access to complex procedures. More than 300 of RadNet’s MR, CT, PET/CT, and Ultrasound systems are now connected with DeepHealth’s TechLive™ solution, resulting in increased patient throughput and improved quality through remotely matching expert staff with complex modalities in real-time.
Over the past decade, radiology workloads have steadily increased, while the number of qualified technologists have not grown proportionally. In a pilot deployment at 64 locations inside of RadNet’s New York area facilities, TechLive™ significantly contributed to a
"TechLive™ represents a paradigm shift in how we approach imaging operations," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. "By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth’s vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries."
About DeepHealth
DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth, Kheiron, and iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. https://deephealth.com/
About RadNet, Inc.
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit http://www.radnet.com.
DeepHealth Contact
Andra Axente
Director of Communications
+31614440971
andra.axente@deephealth.com
RadNet, Inc. Contact
Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek, “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the streamlining of delivery and deployment across healthcare facilities, and TechLive creating a foundation for more efficient, financially sustainable and high-quality patient care across the broadest set of imaging modalities, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet nor its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.
Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.
FAQ
What is RadNet's TechLive™ and what FDA clearance did it receive?
How successful was the RadNet (RDNT) TechLive™ pilot program?
How many imaging systems has RadNet connected with TechLive™?
What problem does RadNet's TechLive™ solve in the radiology industry?
How does TechLive™ benefit ultrasound procedures specifically?
